U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 240

1.
Effects of metformin, saxagliptin and repaglinide on gut microbiota in high-fat diet/streptozocin-induced type 2 diabetic mice
Yangchen Tang, Mengli Yan, Zemin Fang, Song Jin, Tingjuan Xu
BMJ Open Diabetes Res Care. 2024; 12(3): e003837. Published online 2024 May 6. doi: 10.1136/bmjdrc-2023-003837
PMCID:
PMC11085777
AbstractArticlePDF–12M
2.
Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences
Mahamadou D. Camara, Yitian Zhou, Taís Nóbrega De Sousa, José P. Gil, Abdoulaye A. Djimde, Volker M. Lauschke
Hum Genomics. 2024; 18: 40. Published online 2024 Apr 22. doi: 10.1186/s40246-024-00610-y
PMCID:
PMC11034136
AbstractArticlePDF–3.8M
3.
Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, Tamara Poljičanin, Sandra Karanović Štambuk, Hana Brborović, Ognjen Brborović
PLoS One. 2024; 19(3): e0301056. Published online 2024 Mar 27. doi: 10.1371/journal.pone.0301056
PMCID:
PMC10971752
AbstractArticlePDF–463K
4.
Repaglinide–Solid Lipid Nanoparticles in Chitosan Patches for Transdermal Application: Box–Behnken Design, Characterization, and In Vivo Evaluation
Hany S M Ali, Nader Namazi, Hossein M Elbadawy, Abdelaziz A A El-Sayed, Sameh A Ahmed, Rawan Bafail, Mohannad A Almikhlafi, Yaser M Alahmadi
Int J Nanomedicine. 2024; 19: 209–230. Published online 2024 Jan 10. doi: 10.2147/IJN.S438564
PMCID:
PMC10788056
AbstractArticlePDF–7.3M
5.
Effects of in vitro repaglinide supplementation on improving sperm motility parameters, viability, and DNA integrity in normozoospermic and asthenozoospermic men
Eshrat Kalehoei, Mehri Azadbakht, Nazanin Karimi, Fatemeh Nowrouzi, Nasrin Jalilian, Farahnaz Keshavarzi
JBRA Assist Reprod. 2023 Jul-Sep; 27(3): 482–489. doi: 10.5935/1518-0557.20230038
PMCID:
PMC10712804
AbstractArticlePDF–3.6M
6.
Formulation of Deformable Liponiosomal Hybrid of Repaglinide: In vitro Characterization and Evaluation of the Anti-Diabetic Effect
Ali F Abdelwahab, Alshimaa M Abdelmohymen, Nada M Mostafa, Galal Magdy, Eman A Mazyed
Int J Nanomedicine. 2023; 18: 7417–7440. Published online 2023 Dec 7. doi: 10.2147/IJN.S434840
PMCID:
PMC10712347
AbstractArticlePDF–15M
7.
Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice
Rafael Gonzalo-Gobernado, Laura Moreno-Martínez, Paz González, Xose Manuel Dopazo, Ana Cristina Calvo, Isabel Pidal-Ladrón de Guevara, Elisa Seisdedos, Rodrigo Díaz-Muñoz, Britt Mellström, Rosario Osta, José Ramón Naranjo
Int J Mol Sci. 2023 Nov; 24(21): 15783. Published online 2023 Oct 30. doi: 10.3390/ijms242115783
PMCID:
PMC10648964
AbstractArticlePDF–3.7M
8.
Harmonic Vibrational Frequency Simulation of Pharmaceutical Molecules via a Novel Multi-Molecular Fragment Interception Method
Linjie Wang, Pengtu Zhang, Yali Geng, Zaisheng Zhu, Shiling Yuan
Molecules. 2023 Jun; 28(12): 4638. Published online 2023 Jun 8. doi: 10.3390/molecules28124638
PMCID:
PMC10304189
AbstractArticlePDF–3.2M
9.
A single‐centre, open‐label, single‐arm, fixed‐sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients
Tao Dai, Zhenzhou Xu, Liang Huang, Yike Wang, Gongqian Zeng, Mingji Ye, Kan Liu, Fuhua Zeng, Shusuan Jiang, Weiqing Han, Jingying Cao
Br J Clin Pharmacol. 2023 Feb; 89(2): 874–886. Published online 2022 Oct 9. doi: 10.1111/bcp.15528
PMCID:
PMC10092624
AbstractArticlePDF–728K
10.
Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats
Shahinaze A. Fouad, Mahmoud H. Teaima, Mostafa I. Gebril, Fathy I. Abd Allah, Mohamed A. El-Nabarawi, Sammar Fathy Elhabal
Drug Deliv. 2023; 30(1): 2181747. Published online 2023 Feb 20. doi: 10.1080/10717544.2023.2181747
PMCID:
PMC9943253
AbstractArticlePDF–2.4M
11.
Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants
Matthias Hoch, Tirtha Sengupta, Florence Hourcade‐Potelleret
Clin Transl Sci. 2022 Jun; 15(6): 1406–1416. Published online 2022 Mar 15. doi: 10.1111/cts.13252
PMCID:
PMC9199882
AbstractArticlePDF–773K
12.
In vitro maturation medium supplementation: utilization of repaglinide, L-carnitine, and mesenchymal stem cell-conditioned medium to improve developmental competence of oocytes derived from endometriosis mouse models
E. Kalehoei, M. Moradi, M. Azadbakht, H. Zhaleh, M. Parvini, S. Cheraghbaeigi, S. Saghari
Braz J Med Biol Res. 2022; 55: e11948. Published online 2022 Apr 27. doi: 10.1590/1414-431X2022e11948
PMCID:
PMC9054032
AbstractArticlePDF–683K
13.
Clinical Effects of Exercise Rehabilitation Combined with Repaglinide in the Treatment of Diabetes
Yan Li, Xi Wang, Ying Zhang
Dis Markers. 2022; 2022: 6309188. Published online 2022 Mar 25. doi: 10.1155/2022/6309188
PMCID:
PMC8975691
AbstractArticlePDF–413K
14.
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia
Young Hee Nam, Colleen M. Brensinger, Warren B. Bilker, James H. Flory, Charles E. Leonard, Sean Hennessy
Clin Pharmacol Ther. Author manuscript; available in PMC 2023 Jan 1.
Published in final edited form as: Clin Pharmacol Ther. 2022 Jan; 111(1): 218–226. Published online 2021 Aug 23. doi: 10.1002/cpt.2377
PMCID:
PMC8678147
AbstractArticlePDF–587K
15.
Meglitinide (repaglinide) therapy in permanent neonatal diabetes mellitus: two case reports
Maryam Razzaghy-Azar, Mitra Nourbakhsh, Ali Talea, Mahsa Mohammad Amoli, Mona Nourbakhsh, Bagher Larijani
J Med Case Rep. 2021; 15: 535. Published online 2021 Oct 25. doi: 10.1186/s13256-021-03052-5
PMCID:
PMC8543822
AbstractArticlePDF–897K
16.
Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation, characterization, pharmacokinetics, and in situ intestinal perfusion
Lei Wu, Lin Zhao, Xitong Su, Peng Zhang, Guixia Ling
Drug Deliv. 2020; 27(1): 400–409. Published online 2019 Nov 15. doi: 10.1080/10717544.2019.1689313
PMCID:
PMC8216444
AbstractArticlePDF–2.0M
17.
Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study
Siyao He, Xin Qian, Yanyan Chen, Xiaoxia Shen, Bo Zhang, Xiaoping Chen, Xiangjin Xu, Guangwei Li
J Diabetes Res. 2021; 2021: 5534387. Published online 2021 Jun 10. doi: 10.1155/2021/5534387
PMCID:
PMC8213465
AbstractArticlePDF–718K
18.
HIGH-PERFORMANCE AFFINITY CHROMATOGRAPHIC STUDIES OF REPAGLINIDE AND NATEGLINIDE INTERACTIONS WITH NORMAL AND GLYOXAL- OR METHYLGLYOXAL-MODIFIED HUMAN ALBUMIN SERUM
Susan T. Ovbude, Pingyang Tao, Zhao Li, David S. Hage
J Pharm Biomed Anal. Author manuscript; available in PMC 2022 Jul 15.
Published in final edited form as: J Pharm Biomed Anal. 2021 Jul 15; 201: 114097. Published online 2021 Apr 22. doi: 10.1016/j.jpba.2021.114097
PMCID:
PMC8169628
AbstractArticlePDF–683K
19.
Drug treatments for managing cystic fibrosis‐related diabetes
Cochrane Database Syst Rev. 2020; 2020(10): CD004730. Published online 2020 Oct 19. doi: 10.1002/14651858.CD004730.pub5
PMCID:
PMC8094754
AbstractArticlePDF–579K
20.
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
Cochrane Database Syst Rev. 2020; 2020(11): CD013516. Published online 2020 Nov 19. doi: 10.1002/14651858.CD013516.pub2
PMCID:
PMC8092670
AbstractArticlePDF–2.4M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center